Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVJF) FCF Margin (2016 - 2025)

Historic FCF Margin for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to 42.84%.

  • Teva Pharmaceutical Industries' FCF Margin rose 87400.0% to 42.84% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.46%, marking a year-over-year increase of 19100.0%. This contributed to the annual value of 12.46% for FY2025, which is 19100.0% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' FCF Margin is 42.84%, which was up 87400.0% from 5.2% recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' FCF Margin peaked at 47.5% during Q4 2023, and registered a low of 13.94% during Q1 2021.
  • Its 5-year average for FCF Margin is 8.01%, with a median of 4.17% in 2025.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -180000bps in 2021, then soared by 261000bps in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' FCF Margin (Quarter) stood at 7.39% in 2021, then surged by 190bps to 21.4% in 2022, then skyrocketed by 122bps to 47.5% in 2023, then dropped by -28bps to 34.1% in 2024, then rose by 26bps to 42.84% in 2025.
  • Its FCF Margin was 42.84% in Q4 2025, compared to 5.2% in Q3 2025 and 3.14% in Q2 2025.